Preprint
via Europe PMC
Glioblastoma Tumors with Decelerated Epigenetic Aging Are Characterized by Glutamatergic Neuronal Activity and Stemness
Motevasseli M, Eterafi M, Alaei H, Zandi P, Shajari N, Tabrizi M, Safarzadeh E.
· 2026
Abstract
<h4>Introduction</h4> Gliomas integrate into neural circuits and heighten neuronal excitability, engaging in bidirectional communication whereby neuronal activity promotes tumor growth and proliferation. Aging reshapes the brain microenvironment through extracellular matrix changes, altered secretory factors, and immune dysfunction, creating conditions permissive to tumorigenesis and limiting immunotherapy efficacy in glioblastoma. However, its effect on neuronal excitability and signaling in glioblastoma remains poorly understood. <h4>Methods</h4> We developed a novel classification system for glioblastoma by leveraging three classes of DNA methylation-based aging biomarkers: chronological, biological, and mitotic clocks. This approach stratified tumors into accelerated and decelerated epigenetic aging subtypes, which we then characterized at the molecular, functional, and clinical levels using multimodal analyses. Guided by these profiles, we evaluated the in vitro effects of the FDA-approved agents levetiracetam and riluzole, alone and in combination with temozolomide, on U87MG and A172 cell lines. Specifically, we assessed changes in cell viability, apoptosis, and the expression of marker genes related to stemness, neuronal hyperexcitability, and immunosuppression. <h4>Results</h4> Tumors with decelerated epigenetic aging showed expression modules and CpG hypomethylation associated with neuronal activity and stemness, and carried significantly worse prognosis. Single-cell and spatial multi-omics analyses revealed enrichment for neurons and malignant neural stem-like cells in these tumors. They also displayed enhanced intercellular communication, driven predominantly by glutamate signaling across the malignant, neuronal, and immune compartments of the tumor microenvironment. In vitro pharmacological inhibition of glutamatergic signaling with levetiracetam and riluzole reduced cell viability, induced apoptosis, and suppressed expression of stemness, neuronal hyperexcitability, and immunosuppression markers. Both agents potentiated the cytotoxic and apoptotic effects of temozolomide, supporting glutamatergic inhibition as a strategy for improving chemosensitivity. <h4>Conclusion</h4> By establishing a framework for decoding glioblastoma heterogeneity through epigenetic aging, we identified the glutamatergic pathway as a clinically actionable vulnerability. Our findings suggest that combining anti-glutamatergic therapies with temozolomide exerts synergistic antitumor effects while mitigating adverse chemotherapy-induced phenotypes, such as increased stemness, neuronal hyperexcitability, and immunosuppression, thereby laying the groundwork for novel therapeutic strategies. <h4>Graphical Abstract</h4>
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.64898/2026.08.29.747960
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
M, M., M, E., H, A., P, Z., N, S., M, T., & E., S. (2026). Glioblastoma Tumors with Decelerated Epigenetic Aging Are Characterized by Glutamatergic Neuronal Activity and Stemness. https://doi.org/10.64898/2026.08.29.747960
Vancouver
M M, M E, H A, P Z, N S, M T, et al. Glioblastoma Tumors with Decelerated Epigenetic Aging Are Characterized by Glutamatergic Neuronal Activity and Stemness. 2026. doi:10.64898/2026.08.29.747960.
BibTeX
@unpublished{motevasseli2026Gliobl,
title = {Glioblastoma Tumors with Decelerated Epigenetic Aging Are Characterized by Glutamatergic Neuronal Activity and Stemness},
author = {Motevasseli M and Eterafi M and Alaei H and Zandi P and Shajari N and Tabrizi M and Safarzadeh E.},
year = {2026},
doi = {10.64898/2026.08.29.747960},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Proceedings of the National Academy of Sciences 2026
Open access · CC-BY
Histone modification clocks for robust cross-species biological age prediction and elucidating senescence regulation
Frontiers in immunology 2026
Open access · OA
Towards a personalized perspective on gliomas: an epigenetic-immuno-inflammatory aging framework.
Frontiers in Cellular Neuroscience 2015
Open access · CC-BY
Dynamic DNA methylation in the brain: a new epigenetic mark for experience-dependent plasticity
Aging Cell 2024
Open access · CC-BY
Hungry for biomarkers of aging
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
ComputAgeBench: Epigenetic Aging Clocks Benchmark
Immunologic research 2026
Citation only